XML 62 R38.htm IDEA: XBRL DOCUMENT v3.7.0.1
- Condensed Consolidated Statement of Operations (Details) - USD ($)
$ / shares in Units, shares in Millions, $ in Millions
 3 Months Ended 9 Months Ended
Oct. 01, 2016
Sep. 26, 2015
Oct. 01, 2016
Sep. 26, 2015
Error Corrections and Prior Period Adjustments Restatement [Line Items]        
Net sales $ 1,261.6 $ 1,273.1 $ 3,949.3 [1] $ 3,655.6 [1]
Cost of sales 777.1 737.9 2,385.2 2,150.0
Gross profit 484.5 535.2 1,564.1 1,505.6
Operating expenses        
Distribution 21.6 24.9 65.9 63.3
Research and development 50.2 41.6 142.5 139.7
Selling 154.6 167.9 506.9 391.6
Administration 105.4 123.3 317.2 343.1
Impairment charges 1,614.4 0.0 2,028.8 6.8
Restructuring 6.6 2.2 17.9 3.1
Total operating expenses 1,952.8 359.9 3,079.2 947.6
Operating income (loss) (1,468.3) 175.3 (1,515.1) [1] 558.0 [1]
Tysabri® royalty stream - change in fair value 377.4 (173.8) 1,492.6 (205.4)
Interest expense, net 54.6 43.4 163.2 132.7
Other (income) expense, net 1.0 10.9 32.4 284.8
Loss on extinguishment of debt 0.7 0.0 1.1 0.9
Income (loss) before income taxes (1,902.0) 294.8 (3,204.4) 345.0
Income tax expense (benefit) (311.8) 33.9 (550.7) 128.6
Net income (loss) $ (1,590.2) $ 260.9 $ (2,653.7) $ 216.4
Income (loss) per share        
Basic income (loss) per share (in dollars per share) $ (11.10) $ 1.78 $ (18.53) $ 1.50
Diluted income (loss) per share (in dollars per share) $ (11.10) $ 1.78 $ (18.53) $ 1.50
Weighted-average shares outstanding        
Basic (in shares) 143.3 146.3 143.2 144.4
Diluted (in shares) 143.3 146.9 143.2 145.0
Previously Reported        
Error Corrections and Prior Period Adjustments Restatement [Line Items]        
Net sales $ 1,354.9 $ 1,344.7 $ 4,219.1 $ 3,925.4
Cost of sales 848.6 795.9 2,622.7 2,369.7
Gross profit 506.3 548.8 1,596.4 1,555.7
Operating expenses        
Distribution 21.6 24.9 65.9 63.3
Research and development 50.2 41.6 142.5 139.7
Selling 154.6 167.9 506.9 391.6
Administration 108.6 123.6 316.8 343.3
Impairment charges 1,679.9   2,127.1 0.0
Restructuring 6.6 2.2 17.9 3.1
Total operating expenses 2,021.5 360.2 3,177.1 941.0
Operating income (loss) (1,515.2) 188.6 (1,580.7) 614.7
Tysabri® royalty stream - change in fair value 0.0 0.0 0.0 0.0
Interest expense, net 54.6 43.4 163.2 132.7
Other (income) expense, net 1.0 13.0 34.1 294.2
Loss on extinguishment of debt 0.7 0.0 1.1 0.9
Income (loss) before income taxes (1,571.5) 132.2 (1,779.1) 186.9
Income tax expense (benefit) (316.3) 19.6 (383.7) 112.7
Net income (loss) $ (1,255.2) $ 112.6 $ (1,395.4) $ 74.2
Income (loss) per share        
Basic income (loss) per share (in dollars per share) $ (8.76) $ 0.77 $ (9.74) $ 0.51
Diluted income (loss) per share (in dollars per share) $ (8.76) $ 0.77 $ (9.74) $ 0.51
Weighted-average shares outstanding        
Basic (in shares) 143.3 146.3 143.2 144.4
Diluted (in shares) 143.3 146.9 143.2 145.0
Tysabri® | Adjustments        
Error Corrections and Prior Period Adjustments Restatement [Line Items]        
Net sales $ (92.4) $ (83.1) $ (267.0) $ (244.6)
Cost of sales (72.5) (72.5) (217.5) (217.5)
Gross profit (19.9) (10.6) (49.5) (27.1)
Operating expenses        
Distribution 0.0 0.0 0.0 0.0
Research and development 0.0 0.0 0.0 0.0
Selling 0.0 0.0 0.0 0.0
Administration 0.0 0.0 0.0 0.0
Impairment charges 0.0   0.0 0.0
Restructuring 0.0 0.0 0.0 0.0
Total operating expenses 0.0 0.0 0.0 0.0
Operating income (loss) (19.9) (10.6) (49.5) (27.1)
Tysabri® royalty stream - change in fair value 377.4 (173.8) 1,492.6 (205.4)
Interest expense, net 0.0 0.0 0.0 0.0
Other (income) expense, net 0.2 0.7 0.4 0.8
Loss on extinguishment of debt 0.0 0.0 0.0 0.0
Income (loss) before income taxes (397.5) 162.5 (1,542.5) 177.5
Income tax expense (benefit) (49.7) 20.3 (192.8) 22.2
Net income (loss) $ (347.8) $ 142.2 $ (1,349.7) $ 155.3
Income (loss) per share        
Basic income (loss) per share (in dollars per share) $ (2.43) $ 0.97 $ (9.42) $ 1.08
Diluted income (loss) per share (in dollars per share) $ (2.43) $ 0.97 $ (9.42) $ 1.08
Other | Adjustments        
Error Corrections and Prior Period Adjustments Restatement [Line Items]        
Net sales $ (0.9) $ 11.5 $ (2.8) $ (25.2)
Cost of sales 1.0 14.5 (20.0) (2.2)
Gross profit (1.9) (3.0) 17.2 (23.0)
Operating expenses        
Distribution 0.0 0.0 0.0 0.0
Research and development 0.0 0.0 0.0 0.0
Selling 0.0 0.0 0.0 0.0
Administration (3.2) (0.3) 0.4 (0.2)
Impairment charges (65.5)   (98.3) 6.8
Restructuring 0.0 0.0 0.0 0.0
Total operating expenses (68.7) (0.3) (97.9) 6.6
Operating income (loss) 66.8 (2.7) 115.1 (29.6)
Tysabri® royalty stream - change in fair value 0.0 0.0 0.0 0.0
Interest expense, net 0.0 0.0 0.0 0.0
Other (income) expense, net (0.2) (2.8) (2.1) (10.2)
Loss on extinguishment of debt 0.0 0.0 0.0 0.0
Income (loss) before income taxes 67.0 0.1 117.2 (19.4)
Income tax expense (benefit) 54.2 (6.0) 25.8 (6.3)
Net income (loss) $ 12.8 $ 6.1 $ 91.4 $ (13.1)
Income (loss) per share        
Basic income (loss) per share (in dollars per share) $ 0.09 $ 0.04 $ 0.63 $ (0.09)
Diluted income (loss) per share (in dollars per share) $ 0.09 $ 0.04 $ 0.63 $ (0.09)
BCH Deferred Tax Matters Misstatement | Adjustments        
Operating expenses        
Income tax expense (benefit) $ 39.8 $ (19.5) $ 13.4 $ (13.0)
Adjustments to Income Taxes Accounted For Under ASC 740 | Adjustments        
Operating expenses        
Income tax expense (benefit) $ 14.2 $ 13.6 6.2 13.4
BCH Belgium Distribution Contracts Misstatement | Adjustments        
Operating expenses        
Income tax expense (benefit)     $ 3.5 $ (3.3)
[1] The BCH segment was created on March 30, 2015 as a result of the Omega acquisition, thus data for the nine months ended September 26, 2015 includes only six months of results from operations attributable to Omega.